BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2162 related articles for article (PubMed ID: 26560028)

  • 1. Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer.
    Zheng X; Carstens JL; Kim J; Scheible M; Kaye J; Sugimoto H; Wu CC; LeBleu VS; Kalluri R
    Nature; 2015 Nov; 527(7579):525-530. PubMed ID: 26560028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stabilized epithelial phenotype of cancer cells in primary tumors leads to increased colonization of liver metastasis in pancreatic cancer.
    Carstens JL; Yang S; Correa de Sampaio P; Zheng X; Barua S; McAndrews KM; Rao A; Burks JK; Rhim AD; Kalluri R
    Cell Rep; 2021 Apr; 35(2):108990. PubMed ID: 33852841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Knockdown of FOXO3a induces epithelial-mesenchymal transition and promotes metastasis of pancreatic ductal adenocarcinoma by activation of the β-catenin/TCF4 pathway through SPRY2.
    Li J; Yang R; Dong Y; Chen M; Wang Y; Wang G
    J Exp Clin Cancer Res; 2019 Jan; 38(1):38. PubMed ID: 30691517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Grainyhead-like 2 (GRHL2) regulates epithelial plasticity in pancreatic cancer progression.
    Nishino H; Takano S; Yoshitomi H; Suzuki K; Kagawa S; Shimazaki R; Shimizu H; Furukawa K; Miyazaki M; Ohtsuka M
    Cancer Med; 2017 Nov; 6(11):2686-2696. PubMed ID: 28960866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Skeletal Muscle-Derived Irisin Enhances Gemcitabine Sensitivity and Suppresses Migration Ability in Pancreatic Ductal Adenocarcinoma.
    Sugimoto T; Iwagami Y; Kobayashi S; Yamanaka C; Sasaki K; Yamada D; Tomimaru Y; Asaoka T; Noda T; Takahashi H; Shimizu J; Doki Y; Eguchi H
    Ann Surg Oncol; 2024 Jun; 31(6):3718-3736. PubMed ID: 38502294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LAMC2 promotes cancer progression and gemcitabine resistance through modulation of EMT and ATP-binding cassette transporters in pancreatic ductal adenocarcinoma.
    Okada Y; Takahashi N; Takayama T; Goel A
    Carcinogenesis; 2021 Apr; 42(4):546-556. PubMed ID: 33624791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypoxia induces TWIST-activated epithelial-mesenchymal transition and proliferation of pancreatic cancer cells in vitro and in nude mice.
    Chen S; Chen JZ; Zhang JQ; Chen HX; Yan ML; Huang L; Tian YF; Chen YL; Wang YD
    Cancer Lett; 2016 Dec; 383(1):73-84. PubMed ID: 27693633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. miR-125a-3p is responsible for chemosensitivity in PDAC by inhibiting epithelial-mesenchymal transition via Fyn.
    Liu G; Ji L; Ke M; Ou Z; Tang N; Li Y
    Biomed Pharmacother; 2018 Oct; 106():523-531. PubMed ID: 29990840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abrogation of glutathione peroxidase-1 drives EMT and chemoresistance in pancreatic cancer by activating ROS-mediated Akt/GSK3β/Snail signaling.
    Meng Q; Shi S; Liang C; Liang D; Hua J; Zhang B; Xu J; Yu X
    Oncogene; 2018 Nov; 37(44):5843-5857. PubMed ID: 29980787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CCR7 regulates Twist to induce the epithelial-mesenchymal transition in pancreatic ductal adenocarcinoma.
    Li K; Xu B; Xu G; Liu R
    Tumour Biol; 2016 Jan; 37(1):419-24. PubMed ID: 26219899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic programming of distinct cancer stem cells promotes metastasis of pancreatic ductal adenocarcinoma.
    Nimmakayala RK; Leon F; Rachagani S; Rauth S; Nallasamy P; Marimuthu S; Shailendra GK; Chhonker YS; Chugh S; Chirravuri R; Gupta R; Mallya K; Prajapati DR; Lele SM; C Caffrey T; L Grem J; Grandgenett PM; Hollingsworth MA; Murry DJ; Batra SK; Ponnusamy MP
    Oncogene; 2021 Jan; 40(1):215-231. PubMed ID: 33110235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fascin is regulated by slug, promotes progression of pancreatic cancer in mice, and is associated with patient outcomes.
    Li A; Morton JP; Ma Y; Karim SA; Zhou Y; Faller WJ; Woodham EF; Morris HT; Stevenson RP; Juin A; Jamieson NB; MacKay CJ; Carter CR; Leung HY; Yamashiro S; Blyth K; Sansom OJ; Machesky LM
    Gastroenterology; 2014 May; 146(5):1386-96.e1-17. PubMed ID: 24462734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gemcitabine enhances cell invasion via activating HAb18G/CD147-EGFR-pSTAT3 signaling.
    Xu BQ; Fu ZG; Meng Y; Wu XQ; Wu B; Xu L; Jiang JL; Li L; Chen ZN
    Oncotarget; 2016 Sep; 7(38):62177-62193. PubMed ID: 27556697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. S100A14 promotes progression and gemcitabine resistance in pancreatic cancer.
    Zhu H; Gao W; Li X; Yu L; Luo D; Liu Y; Yu X
    Pancreatology; 2021 Apr; 21(3):589-598. PubMed ID: 33579599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transcriptomic and functional analysis of ANGPTL4 overexpression in pancreatic cancer nominates targets that reverse chemoresistance.
    Gordon ER; Wright CA; James M; Cooper SJ
    BMC Cancer; 2023 Jun; 23(1):524. PubMed ID: 37291514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Involvement of epithelial to mesenchymal transition in the development of pancreatic ductal adenocarcinoma.
    Satoh K; Hamada S; Shimosegawa T
    J Gastroenterol; 2015 Feb; 50(2):140-6. PubMed ID: 25216997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The long non-coding RNA HOTTIP promotes progression and gemcitabine resistance by regulating HOXA13 in pancreatic cancer.
    Li Z; Zhao X; Zhou Y; Liu Y; Zhou Q; Ye H; Wang Y; Zeng J; Song Y; Gao W; Zheng S; Zhuang B; Chen H; Li W; Li H; Li H; Fu Z; Chen R
    J Transl Med; 2015 Mar; 13():84. PubMed ID: 25889214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paracrine IL-6 signaling mediates the effects of pancreatic stellate cells on epithelial-mesenchymal transition via Stat3/Nrf2 pathway in pancreatic cancer cells.
    Wu YS; Chung I; Wong WF; Masamune A; Sim MS; Looi CY
    Biochim Biophys Acta Gen Subj; 2017 Feb; 1861(2):296-306. PubMed ID: 27750041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-tumor activity of cediranib, a pan-vascular endothelial growth factor receptor inhibitor, in pancreatic ductal adenocarcinoma cells.
    Momeny M; Alishahi Z; Eyvani H; Esmaeili F; Zaghal A; Ghaffari P; Tavakkoly-Bazzaz J; Alimoghaddam K; Ghavamzadeh A; Ghaffari SH
    Cell Oncol (Dordr); 2020 Feb; 43(1):81-93. PubMed ID: 31512195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epithelial-to-mesenchymal transition in pancreatic ductal adenocarcinoma and pancreatic tumor cell lines: the role of neutrophils and neutrophil-derived elastase.
    Grosse-Steffen T; Giese T; Giese N; Longerich T; Schirmacher P; Hänsch GM; Gaida MM
    Clin Dev Immunol; 2012; 2012():720768. PubMed ID: 23227088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 109.